Brief: Cantargia, Otsuka Sign Deal On Rights For Development Of CAN10 Il1rap Immunology Program
15/07/2025 07:50
July 15 (Reuters) - Cantargia AB CANTA.ST: ANNOUNCES THE ACQUISITION OF ITS CAN10 IL1RAP IMMUNOLOGY PROGRAM BY OTSUKA PHARMACEUTICAL ELIGIBLE FOR UP TO USD 580 MILLION IN MILESTONES TO RECEIVE USD 33 MILLION UPFRONT OTSUKA ALSO BUYS 3G5 AND NEGOTIATION RIGHTS FOR IL-1RAP Source text: ID:nMFN4vtdVy Further company coverage: CANTA.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Cantargia AB
See all newsBrief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML